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Running head: Comparison of Compass and Humphrey Field Analyzer 42 
  43 
Abstract 44 
Purpose: To evaluate relative diagnostic precision and test retest variability of two devices, 45 
the Compass (CMP, CenterVue, Italy) fundus perimeter and the Humphrey Field Analyzer 46 
(HFA, Zeiss, Dublin), in detecting glaucomatous optic neuropathy (GON). 47 
Design: Multicentre cross-sectional case–control study. 48 
Subjects: We sequentially enrolled 499 glaucoma patients and 444 normal subjects to analyse 49 
relative precision. A separate group of 44 glaucoma patients and 54 normal subjects was 50 
analysed to assess test – retest variability.  51 
Methods: One eye of the recruited subjects was tested with the index tests: HFA (SITA 52 
Standard strategy) and CMP (ZEST strategy) with a 24-2 grid. The reference test for GON was 53 
specialist evaluation of fundus photographs or OCT, independent of the visual field. For both 54 
devices, linear regression was used to calculate the sensitivity decrease with age in the 55 
normal group to compute pointwise Total Deviation (TD) values and Mean Deviation (MD). 56 
We derived 5% and 1% pointwise normative limits. MD and the total number of TD values 57 
below 5% (TD 5%) or 1% (TD 1%) limits per field were used as classifiers.  58 
Main Outcome Measures: We used partial Receiver Operating Characteristic (ROC) curves 59 
and partial Area Under the Curve (pAUC) to compare the diagnostic precision of the devices. 60 
Pointwise Mean Absolute Deviation (MAD) and Bland Altman plots for the mean sensitivity 61 
(MS) were computed to assess test- retest variability. 62 
Results: Retinal sensitivity was generally lower with CMP, with an average mean difference of 63 
1.85 ± 0.06 dB (Mean ± Standard Error, p < 0.001) in healthy subjects and 1.46 ± 0.05 dB 64 
(Mean ± Standard Error, p < 0.001) in patients with glaucoma. Both devices showed similar 65 
discriminative power. The MD metric had marginally better discrimination with CMP (pAUC 66 
difference ± Standard Error, 0.019 ± 0.009, p = 0.035). The 95% limits of agreement for the 67 
MS were reduced by 13% in CMP compared to HFA in glaucoma subjects, and by 49% in 68 
normal subjects. MAD was very similar, with no significant differences.  69 
Conclusions: Relative diagnostic precision of the two devices is equivalent. Test-retest 70 
variability of mean sensitivity for CMP was better than for HFA.   71 
Standard Automated Perimetry (SAP) is used to assess the visual field (VF) and is a key 72 
examination for detection, diagnosis and follow up in glaucoma. SAP typically uses stimuli of 73 
varying intensities to assess the differential light sensitivity at static locations across the VF. 74 
The examination demands strong cooperation1 from test subjects; they are required to 75 
maintain central fixation and respond timely and accurately to the presented stimuli. Fixation 76 
instability might be an unavoidable feature of a person’s vision, especially with advanced age 77 
and macular damage2. One proposed solution has been to incorporate live fundus tracking in 78 
the macular perimetric exam to compensate for eye movements in unstable fixation 3.  79 
Recently, a novel instrument, the COMPASS fundus perimeter (CMP, CenterVue, Padua, Italy), 80 
has successfully employed a live fundus tracking technology for wide field (30 degrees) VF 81 
assessment 4, 5 yielding results comparable with the Humphrey Field Analyzer (HFA) in a 82 
preliminary study 4. The CMP captures images of the fundus during the perimetric 83 
examination using a scanning laser ophthalmoscope. This design feature is intended to afford 84 
compensation for eye movements when the stimuli are presented at predetermined test 85 
locations. Moreover, the instrument provides colour images of the fundus and optic nerve that 86 
can be mapped to the final perimetric results potentially providing clinically useful 87 
information about structure and function in one assessment.  88 
Diagnostic accuracy studies are used to certify new examinations before they are brought into 89 
clinical practice. The CMP has not yet been scrutinised in this way and this is the main 90 
purpose of our investigation. Studies investigating relative diagnostic accuracy are at risk of 91 
bias due to shortcomings in design and conduct. For this reason, we designed our study to 92 
follow appropriate guidelines on this specific aim 6, 7.  93 
 Our cross-sectional and multicentre study was designed to evaluate and compare two index 94 
tests, namely the CMP and the HFA. One objective was to evaluate and compare test – retest 95 
variability of the two index tests in healthy subjects and patients with glaucomatous optic 96 
neuropathy (GON). We hypothesised that the CMP could obtain a 20% reduction in test-retest 97 
variability on the measurement of the Mean Sensitivity (MS) of the VF. Another objective was 98 
to build a normative database for the CMP and analyse its relative discriminative ability, 99 
compared to HFA, in detecting subjects with GON. We specifically hypothesised that the two 100 
index tests will have equivalent relative diagnostic precision as assessed by partial area under 101 
the receiver operating characteristic (ROC) curve at >75% specificity, across a spectrum of 102 
disease severity. In both analyses, the reference assessment for GON was specialist evaluation 103 
based on the inspection of fundus photograph or Spectral Domain – Optical Coherence 104 
Tomography (SD-OCT) evaluation of the Retinal Nerve Fibre Layer (RNFL), independent of 105 
the VF. A further objective was to evaluate examination times for the CMP and HFA.   106 
 107 
Methods 108 
Data collection for the normative database and discrimination analysis 109 
People were recruited at eight study sites. These were: ASST - Santi Paolo e Carlo, Milan, Italy; 110 
Azienda Ospedaliero Universitaria Santa Maria della Misericordia di Udine, Udine, Italy; NIHR 111 
Clinical Research Facility at Moorfields Eye Hospital, London, UK; Department of 112 
Ophthalmology and Visual Sciences University of Iowa, 200 Hawkins Drive, Iowa City, IA; 113 
Department of Optometry & Vision Sciences, The University of Melbourne, 114 
Parkville,  Australia; IRCCS Fondazione “G.B. Bietti”, Clinica Oculistica Università degli Studi di 115 
Roma "La Sapienza", Rome, Italy; and Azienda Ospedaliera Sant'Andrea, Rome, Italy). 116 
Recruitment started on 14/09/2015 and concluded on 31/07/2017. Data collection was 117 
planned before the index test and reference standard were performed. The study was 118 
designed to achieve a target number of 1000 glaucoma subjects and 600 healthy subjects for 119 
the normative database and discrimination analysis. However, these targets were not reached 120 
by the termination date of the study. 121 
Participants eligible for inclusion were consecutive adults (18-90 years) with:   122 
• Best corrected visual acuity > 0.8 (if ≤ 50 years old) or >0.6 (if >50 years old) in the 123 
study eye; 124 
• Refraction -10D / +6D; astigmatism ±2D; 125 
• Absence of systemic pathologies that could affect the VF; 126 
• No use of drugs interfering with the correct execution of the perimetric test; 127 
Additional specific inclusion criteria for healthy subjects were: 128 
• Normal optic nerve head in both eyes (no evidence of excavation, rim narrowing or 129 
notching, disc haemorrhages, RNFL thinning); 130 
• Intraocular Pressure (IOP) less than 21 mmHg in both eyes; 131 
• No ocular pathologies, trauma, surgeries (apart from uncomplicated cataract surgery) 132 
in both eyes; 133 
Additional specific inclusion criteria for glaucoma subjects were: 134 
• GON defined as glaucomatous changes to the optic nerve head (ONH) or retinal nerve 135 
fibre layer (RNFL) as determined by a specialist from fundus photograph or SD-OCT, 136 
independently of the VF.  137 
• Patients had to be receiving anti-glaucoma therapy; 138 
• No ocular pathologies, trauma, surgeries (apart from uncomplicated cataract surgery), 139 
other than glaucoma, in both eyes; 140 
Eligible patients were identified based on a clinical diagnosis of GON from the clinical registry 141 
of the glaucoma clinics in the recruiting centres. An expert clinician confirmed the diagnosis of 142 
GON using the imaging data (RNFL SD-OCT or optic nerve photograph) acquired during the 143 
protocol examination (see below). Subjects were recruited consecutively. Since the VF metrics 144 
were not included in the identification of patients with GON, no stratification was planned 145 
according to disease severity. 146 
Eligible healthy participants were identified among staff in the clinics, volunteer registries, 147 
patients’ spouses or partners and patients attending the clinic for reasons other than 148 
glaucoma (for example, for preoperative assessment for cataract in the fellow eye).   149 
If deemed eligible for the study, healthy subjects were recruited consecutively.  150 
Both eyes were examined but only one eye per subject was used in the final analysis, chosen 151 
randomly if both eyes were eligible.  All patients gave their written informed consent to 152 
participate in the study. Ethics Committee approval was obtained (International Ethics 153 
Committee of Milan, Zone A, 22/07/2015, ref: Prot. n° 0019459) and the study was registered 154 
as a clinical trial (ISRCTN13800424). This study adhered to the tenets of the Declaration of 155 
Helsinki. 156 
Each subject had an ophthalmological evaluation following a standard operating procedure 157 
involving assessment of axial length (AL) measurement with the IOL Master (Zeiss) biometer, 158 
SD-OCT of the Optic Nerve Head (ONH) and RNFL, perimetric demonstration (only for 159 
subjects naïve to perimetry); one examination with HFA 24-2 grid SITA Standard to both eyes 160 
and one examination with CMP New Grid (see below), ZEST strategy to both eyes; colour 161 
fundus photo with CMP.  162 
The reference standard to diagnose GON was clinical evaluation by an expert based on RNFL 163 
SD-OCT and/or optic nerve head photography. The rationale for this choice was to avoid any 164 
classification based on VF testing that could have affected the analysis of the relative 165 
discriminative power of the index tests. The two index tests were VF examinations with the 166 
HFA and the CMP. The order of CMP and HFA tests was randomized. The VF examination 167 
performed with the HFA used a 24-2 grid and the SITA – Standard algorithm. Near correction 168 
was used. Fixation was monitored with blind spot tests using the Heijl-Krakau method 8. 169 
The VF examination performed with the CMP employed a testing grid termed ‘New Grid’ 170 
which differs from the HFA 24-2 grid (Supplementary Figure 1, available at 171 
www.aaojournal.org). The New Grid contains all the 52 locations tested with a 24-2, only one 172 
blind spot location (instead of 2 as in the 24-2) and 12 additional points in the macular region 173 
of the VF. The testing strategy was an adaptation of the Zippy Estimation by Sequential 174 
Testing (ZEST) 9, 10. Since the CMP is equipped with autofocusing, no near correction was 175 
needed. Blind spot responses were monitored by projecting stimuli on the location of the 176 
ONH, identified manually by the operator on the baseline infrared fundus image captured at 177 
the beginning of the test. In all the analyses, only the 52 locations in common between the 24-178 
2 and the New Grid were used. 179 
For both devices, VF examinations were considered reliable if the false positive frequency 180 
(FP) was <=18% and the Blind Spot response frequency (BP) was <=25%. If either the HFA or 181 
the CMP VF was deemed unreliable, the eye was excluded from the analysis.  182 
 183 
Statistical analysis 184 
All analyses were based exclusively on the 52 locations in common between the 24-2 grid 185 
(HFA) and the New Grid (CMP). 186 
Differences between the two devices in terms of Mean Sensitivity (MS) and its decrease with 187 
age in healthy subjects were analysed. Since the same eyes were tested with both devices, a 188 
mixed model was used to account for repeated measurements. 189 
Linear regression was used to estimate expected decrease in sensitivity with age in healthy 190 
subjects (dB/years) at each VF location. Total deviation (TD) values for each VF in normal and 191 
glaucoma subjects were calculated as the deviation from the mean trend in the age model for 192 
each location. Mean Deviation (MD) was calculated as the mean of all 24-2 grid TD values in 193 
each VF. Mixed models were used to compare MS and MD values between the two devices in 194 
both the glaucoma and normal groups. MD values were only compared for the glaucoma 195 
group since subjects in the normal group were used to calculate the TD values and are bound 196 
to have a mean MD equal to zero with both devices.  197 
Normative lower limits for each location were calculated for TD values using quantile 198 
regression 11, 12 to account for changes in normal variability with age. Since the variability of 199 
thresholds in healthy subjects is known to increase with age 12, 13, we only allowed for 200 
negative slopes in quantile regression, meaning that normative limits could not shrink with 201 
age. Only the lower 5% and 1% limits for TD values were used in this analysis. 202 
For a fair comparison, TD values and their normative limits were calculated in the same 203 
fashion for HFA and CMP, using the dataset of healthy subjects acquired with each respective 204 
device in this study. 205 
For each VF, we calculated the total number of TD values below the 5% and 1% limits, which 206 
we refer to as TD 5% and TD 1% respectively. 207 
Discrimination ability of the two index tests was measured using MD, TD 5% and TD 1% as 208 
classifiers. These classifiers were used to build Receiver Operating Characteristics (ROC) 209 
curves.  Instead of comparing the whole ROC curve, we analysed the Partial ROC curve (pROC) 210 
down to a minimum specificity of 0.75 to avoid comparing the two devices at too low 211 
specificity values that would fall far outside a clinically useful range. The 95% confidence 212 
intervals for Partial Areas Under the Curves (pAUCs) and p–values for differences were 213 
calculated via bootstrapping14.  214 
The normative data, used to calculate MD and TD metrics and their normative limits, was 215 
composed of the same set of healthy subjects used in the discrimination analysis to calculate 216 
pROC curves and their pAUCs. Therefore, they are only used here to compare the relative 217 
performance of the two devices and not to estimate or report their actual discriminative 218 
power. 219 
To compare test times, CMP average time per location was calculated for each test and the 220 
result multiplied by the number of total points in a 24-2 grid (54 points). This made it 221 
comparable with the testing time read from the printout of the HFA. 222 
 223 
Data collection for test - retest variability 224 
A separate group of glaucoma and healthy subjects was recruited to assess test – retest 225 
variability with the two devices. The target number was 56 subjects with GON and 56 healthy 226 
subjects. The sample size calculation for this part of the study was based on previously 227 
reported data for test - retest in healthy subjects and glaucoma patients 15, 16. All subjects 228 
underwent the same examinations reported for the previous section and the diagnosis of GON 229 
was again confirmed by expert evaluation of the RNFL on SD – OCT images or photographs of 230 
the optic nerve head. Subjects were sequentially recruited in the same way described for the 231 
previous part of the study. No stratification by disease (VF) severity was planned in the 232 
recruitment of glaucoma subjects. All subjects performed four VF tests: two with CMP with a 233 
24-2 grid, ZEST strategy, and two with HFA with a 24-2 grid, SITA Standard strategy, in 234 
randomized order. All examinations were done within a time span of seven days. 235 
  236 
Statistical analysis 237 
Test – retest variability for the overall VF was assessed for MS using Bland – Altman plots and 238 
95% limits of agreement.  Any change in test-retest variability was evaluated by percentage 239 
reduction of the 95% interval of agreement of CMP over HFA. The 95% confidence intervals 240 
for the percentage variation were estimated using a paired bootstrap procedure with 50000 241 
resamples. Mean Absolute Deviation (MAD) was used to assess pointwise test - retest 242 
variability. Differences in MAD, point-wise sensitivity and MS were tested using t-test 243 
statistics from linear mixed models with random effects to account for correlations between 244 
VF measurements from the same subject. 245 
All analyses were done using R version 3.3.1 (R Foundation for Statistical Computing, Vienna, 246 
Austria). 247 
 248 
  249 
Results 250 
Normative database 251 
For this part of the study, 1249 people were screened for eligibility and invited to participate 252 
between 14/09/2015 and 31/07/2017. Of these, 177 subjects did not satisfy the inclusion 253 
criteria and 59 did not complete the examination protocol. Finally, 70 subjects were excluded 254 
because they had at least one unreliable VF test (48 with HFA, 20 with CMP and 2 with both 255 
devices).  256 
Therefore, 444 healthy subjects and 499 glaucoma subjects (patients with GON) were 257 
included in the final analysis. Although no stratification by disease severity was planned, a 258 
wide spectrum of VF severity was obtained by the end of the recruitment. Glaucoma Staging 259 
System 2 (GSS2)17 stage distribution for glaucoma participants is reported in Table 1 and 260 
depicted in Figure 1. 261 
Subjects’ age distributions are reported in Table 1. Mean age (± standard deviation [SD]) was 262 
48 ± 16 and 68 ± 11 years for the normal and glaucoma group respectively. 263 
Average MS was lower with CMP compared to HFA in healthy subjects (Mean ± SD, 27.6 ± 1.6 264 
dB vs 29.4 ± 2.0 dB) and glaucoma subjects (20.5 ± 6.7 dB vs 21.9 ± 6.9 dB) and these 265 
differences were both statistically significant (p < 0.001).  Comparison of the MD values in 266 
healthy subjects has not been performed since this group was used to calculate the normative 267 
average and therefore they were bound to have zero means for both devices. The MD values 268 
from the two devices showed good agreement (Figure 2). Indeed, the average MD (± SD) for 269 
glaucoma subjects was -6.55 ± 6.60 dB (Median: -4.37 dB, IQR: 8.92 dB) with CMP and -6.50 ± 270 
6.63 dB (Median: -4.73 dB, IQR: 9.19 dB) with HFA and this difference was not statistically 271 
significant (p = 0.54).  272 
Average number of presentations (± SD) per location in CMP was 3.02 ± 0.55 for healthy 273 
subjects and 3.70 ± 1.09 for glaucoma patients. Corrected test duration for CMP and test 274 
duration for HFA were similar in both the healthy and glaucoma subjects (see Table 2). 275 
Point-wise sensitivity was generally lower for CMP compared to HFA (Figure 3). The average 276 
mean difference was 1.85 ± 0.06 dB (Mean ± Standard Error, p < 0.001) in healthy subjects 277 
and 1.46 ± 0.05 dB (Mean ± Standard Error, p < 0.001) in patients with glaucoma. Similarly to 278 
the MD, such a difference was reduced when total deviations were considered in glaucoma 279 
subjects (Figure 4), with 7 locations exceeding 1 dB difference.  280 
The MS in the healthy group decreased with age in a similar fashion for both devices, with a 281 
small but statistically significant difference (-0.051 ± 0.005 dB/year for HFA and -0.027 ± 282 
0.005 dB/year for CMP; Mean ± Standard Error; p < 0.001 for slope difference). 283 
The rate of false positives was 1.6 ± 4.0 % for CMP and 1.6 ± 2.3 % for HFA (Mean ± SD). 284 
 285 
Discrimination analysis 286 
Relative discriminative power (relative diagnostic precision) was marginally greater for CMP 287 
when compared to HFA using the MD metric (pAUC difference ± Standard Error, 0.019 ± 288 
0.009, p = 0.035, see Figure 5). There was no statistically significant difference in pAUC 289 
between CMP and HFA when using TD 5% (p =0.18) or TD 1% (p=0.22) as the classifier. 290 
Sensitivity values at selected specificities are reported in Table 3. 291 
 292 
Test – retest variability 293 
By the end of the study, 99 subjects were screened; one subject did not complete all the 294 
examinations and was excluded. In total 54 healthy subjects and 44 glaucoma patients, were 295 
recruited for the test – retest study. Bland – Altman plots are reported in Figure 6. The mean 296 
difference in MS between the first and the second test with the CMP was statistically different 297 
from zero in glaucoma subjects (Mean ± Standard Error, 0.44 ± 0.21 dB, p = 0.041). Bootstrap 298 
distributions of the percentage improvement for the glaucoma group are reported in 299 
Supplementary Figure 2 (available at www.aaojournal.org).  300 
The 95% limits of agreement for MS are depicted in Figure 6. They were 49% (95% CIs: 17% 301 
to 67%) narrower for CMP (Limits of agreement: -1.31, 1.63 dB) compared to HFA (Limits of 302 
agreement: -2.84, 2.91 dB) in the healthy subjects. The 95% limits of agreement were 13% 303 
narrower for CMP (Limits of agreement: -2.26, 3.14 dB) compared to HFA (Limits of 304 
agreement: -3.11, 3.11 dB) in the glaucoma patients but the confidence intervals for these 305 
estimates were very large (95% CI: - 28% to 42%). In glaucoma subjects, the mean test - 306 
retest difference (± SD) was 0.44 ± 1.38 dB for CMP and 0 ± 1.59 dB for HFA. Bland – Altman 307 
plots for all sensitivities are reported in Figure 7. The 95% limits of agreement were generally 308 
narrower for CMP for sensitivities above or equal to 15 dB (Mean Difference: 1.80 dB, 309 
between 15 and 30 dB) and larger below 15 dB (Mean Difference: 5.46 dB).  310 
Pointwise test – retest variability, calculated using the MAD was not significantly different 311 
between CMP and HFA for glaucoma patients (Mean ± SD, CMP: 1.03 ± 1.01 dB, HFA: 1.07 ± 312 
1.16 dB; Mean Difference ± SE, 0.03 ± 0.2 dB, p = 0.88) and for healthy subjects (Mean ± SD, 313 
CMP: 0.59 ± 0.48 dB, HFA: 0.90 ± 1.15 dB; 0.08 ± 0.16 dB, p = 0.62).  314 
  315 
Discussion 316 
This study was designed to compare two index tests, CMP and HFA, in terms of test - retest 317 
variability and relative discriminative power. We recruited a large cohort of 943 subjects (499 318 
patients with glaucoma and 444 healthy subjects) for the discrimination analysis and 98 319 
subjects (44 glaucomatous and 54 healthy) to compare test-retest variability. The reference 320 
standard used for the diagnosis of GON was independent of VF assessment, based on 321 
specialist assessment of ONH colour photography and/or peripapillary RNFL thickness 322 
measured with SD-OCT.  323 
The primary objective was to show a reduction of test – retest variability in the MS of at least 324 
20%. Such a reduction was achieved in healthy subjects (49%), but not in glaucoma subjects, 325 
where the reduction was of 13%. Several factors might have contributed to this result, such as 326 
a more pronounced perimetric learning effect with CMP18-21.  The mean difference in MS in 327 
CMP between the first and the second test was small but statistically significant and this may 328 
be indicative of a learning effect in the glaucoma test - retest cohort. This effect was not seen 329 
in the HFA data. Indeed, despite all glaucoma subjects in our sample having had previous 330 
experience with SAP, the new setup of a fundus perimeter might have created an unfamiliar 331 
testing condition for test takers. In fact, most of them were recruited from glaucoma clinics 332 
and were experienced with HFA. The different threshold acquisition strategies employed by 333 
the two devices may also explain this difference. SITA strategies incorporate spatial 334 
information between neighbouring test locations. Such an approach allows for faster 335 
threshold estimation, but it has been shown to bias the estimates introducing correlations 336 
between neighbouring points 22, 23. On the other hand, the implementation of the ZEST 337 
strategy used in CMP tests each point independently.  Moreover, test - retest variability is 338 
known to increase dramatically at lower sensitivities24-27 and this effect may simply consume 339 
any improvements from adjusting for fixation stability afforded by the tracking in fundus 340 
perimetry. We speculate this is the reason we see much bigger improvement in test-retest 341 
variability in the healthy subjects compared to the patients in this study. This is supported by 342 
the results shown in the Bland-Altman plots for pointwise sensitivities, where it can be 343 
observed that the CMP offers no advantage in test-retest variability compared to HFA at 344 
values below 15 dB. Indeed, the 95% limits of agreement between 11 and 14 dB were larger 345 
for CMP than for HFA. The difference here might be explained by the spatial smoothing and 346 
the use of growth pattern to seed the priors 9, 22 in the SITA strategy, which might play a large 347 
role in reducing the test retest variability in this sensitivity range. However, the clinical utility 348 
of thresholds below 15 dB has been questioned. Indeed, recent evidence suggests that 349 
increasing perimetric contrast all the way to 0 dB may not be clinically useful and sensitivities 350 
obtained at severely damaged visual field locations (<15-19 dB) are unreliable and highly 351 
variable. It could be argued that improvements in tests-retest variability in the upper range of 352 
sensitivity values could be more clinically relevant for progression detection 24-29. However, 353 
this is speculation because only analysis of long-term follow-up of glaucoma subjects with the 354 
CMP will allow the assessment of the real effect of such reduction in variability on earlier 355 
diagnosis of progression.  356 
Additionally, Wyatt et al identified gaze instability as a possible source of variability at the 357 
edges of scotomata30, and tracking might help reduce this effect. However, their analysis was 358 
performed with a 10-2 grid, which has a much finer spacing between locations (2 degrees). 359 
Hence, further investigation is needed to assess the effect of gaze instability in the estimation 360 
of edges on a typical testing grid, such as 24-2 or 30-2.  361 
One limitation of our analysis is that the sample size of the glaucoma test – retest group was 362 
probably too small to reliably assess any differences, as shown by the large confidence 363 
intervals calculated via bootstrapping (Supplementary Figure 2, available at 364 
www.aaojournal.org). Post hoc power calculations based on bootstrap resampling estimated 365 
that 97 glaucoma subjects would have been needed to detect a 20% improvement at a 366 
significance level of 0.05 with 80% power. This is considerably above the initial estimates 367 
obtained from literature data 15, 16 used for designing of the study. Therefore, an additional 368 
investigation with longer test series on a larger sample might be needed to fully assess the 369 
effect of fundus tracking on test – retest variability. 370 
Relative discriminative power for the two index tests (devices) was similar. When compared, 371 
pROC curves calculated using the number of abnormal points per field in the TD maps largely 372 
overlapped, with no evidence for any superiority of either index test (Figure 5). Statistically 373 
significant differences in pROC curves were observed when MD was used as a classifier but 374 
such differences are too small to be likely relevant in clinical situations. These results are 375 
compatible with the fact that, although the actual sensitivity estimates were lower for CMP 376 
compared to HFA, relative indices, such as the MD and TD values, showed only small 377 
differences in glaucoma subjects between the two devices, yielding similar diagnostic ability. 378 
Our results are based on a large sample of individuals from different centres. The different age 379 
clusters, except for people older than 80 years of age, were well represented (Table 1). This 380 
was sufficient to reliably conduct an analysis on relative discriminative power. It is important 381 
to note that, for both devices, all indices used in the discrimination analysis (MD, TD 5% and 382 
TD 1%) and the normative limits for TD were recalculated in the same fashion from the raw 383 
sensitivities and are therefore comparable. However, since the normative limits have been 384 
derived from the same group of healthy subjects used in the discrimination analysis, the 385 
pAUCs are biased and can only be used to compare the relative discriminative ability of the 386 
two devices; they cannot be generalised to estimate the effective discriminative power of 387 
either the CMP or the HFA in clinical practice.  388 
Examination times for the two devices were similar.  Both devices took, on average, 5 to 6 389 
minutes to complete. Testing times had to be corrected prior to comparison due to the greater 390 
number of tested locations with the New Grid used with CMP (65 locations) compared to the 391 
HFA 24-2 grid (54 locations). After corrections, no statistically significant differences could be 392 
detected between the two devices in healthy subjects. A statistical difference was observed in 393 
glaucoma subjects but it is clinically irrelevant (approximately an 11 second difference on 394 
average). Despite similarities in overall examination times, fewer presentations were needed 395 
to estimate thresholds in CMP when compared to HFA at the 52 matching locations. The 396 
number of presentations in healthy subjects was 157 ± 28, which is lower than that reported 397 
for SITA-Standard in the literature (276 for 52 locations) 13. Unfortunately, interpretation of 398 
the examination times of the two devices is difficult for a variety of reasons. For example, CMP 399 
uses catch trials whereas HFA SITA algorithms use response times to estimate false positive 400 
error rates 31. Moreover, the CMP does not project stimuli when the quality in the tracking 401 
signal is low, and this may increase overall examination time. 402 
One limitation of our study is that the glaucoma subjects were not stratified according to 403 
disease severity, since VF data were not used in the diagnosis of GON. This could have 404 
resulted in an uneven representation of glaucoma stages. However, the range of visual field 405 
damage was sufficiently large to allow for a reliable evaluation across the whole spectrum of 406 
glaucoma damage (see Table 1 and Figure 1).  407 
Our recruitment of healthy subjects was not population based and this is another potential 408 
limitation of our study. The main design bias potentially recruiting ‘super-normals’ in studies 409 
of diagnostic precision is to recruit the healthy control group using restriction criteria related 410 
to the outcome of interest 32, for example requiring the healthy controls to have normal visual 411 
fields. We explicitly avoided this bias. Nevertheless, volunteers to clinical studies may be 412 
healthier than an unselected population. This is very hard to avoid, because participants need 413 
to volunteer. However, when we analysed the MD values from the HFA printouts of the 444 414 
healthy subjects, whose calculation is based on the independent internal normative database 415 
built in the device, we found that our sample did not show important deviations from the 416 
normative values. Indeed, the average MD was -1.12 ± 1.64 dB (Median: -0.91 dB, IQR: 1.97 417 
dB). 418 
Finally, the design of this study only allowed for a relative comparison of discriminative 419 
power. Evaluation of the actual diagnostic accuracy would need a further validation on an 420 
independent dataset, to assess how much these findings can be extracted on the general 421 
population. Furthermore, such an evaluation should be conducted on a set of subjects before 422 
the reference test (the clinical diagnosis of GON) is performed, as case-control scenarios are 423 
known to produce biased estimates in discrimination analyses. One option might be to test 424 
glaucoma suspects with the CMP before they are diagnosed as healthy or as having glaucoma. 425 
 426 
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 506 
Figure Legends 507 
Figure 1. GSS217 plot showing the distribution of the 499 subjects with glaucomatous optic 508 
neuropathy in the different stages of the classification. The light grey lines indicate the 509 
boundaries for the different stages. Subjects are classified based on their MD and PSD values 510 
directly taken from the HFA printout. The distribution is approximately uniform across the 511 
different stages.  512 
 513 
Figure 2. The two panels show the agreement of MD (on the left) and MS (on the right) values 514 
between CMP (vertical axis) and HFA (horizontal axis). The black solid line indicates the ideal 515 
perfect agreement. The red dots represent the healthy subjects while the green dots indicate 516 
glaucoma subjects. Differently from MS, MD values did not show important differences 517 
between the two devices. 518 
 519 
Figure 3. Average sensitivity (dB) for each of the 52 locations considered in this analysis for 520 
CMP (A) and HFA (B). The bottom panels report the average pairwise difference per location 521 
in the healthy subjects (C) and for glaucoma patients (D). 522 
 523 
Figure 4. Average total deviation value (dB) for each of the 52 locations considered in this 524 
analysis for CMP (A) and HFA (B). Panel C reports the average pairwise difference (CMP – 525 
HFA) in Total Deviation per location in the glaucoma subjects (in bold all differences 526 
exceeding 1 dB). 527 
 528 
Figure 5. Partial ROC curves built using the MD (in the leftmost panel) as a classifier. The 529 
middle and rightmost panels depict partial ROC curves built using the number of abnormal 530 
locations at two different cut-offs, 5% and 1%, on the probability maps for TD values. There 531 
was no significant difference in either the TD 5% or the TD 1%. MD = Mean Deviation; TD = 532 
Total Deviation. 533 
 534 
Figure 6. Bland – Altman plots for MS. Red dots represent MS measurements from the HFA, 535 
blue dots from the CMP. The shaded grey area indicates the 95 % limits of agreement on the 536 
test-retest difference. The black solid line indicates the mean difference between test-retest 537 
MS measurements. A small offset in the mean difference can be detected in the glaucoma 538 
group with the CMP (bottom – left panel). 539 
 540 
Figure 7. Bland – Altman plots for all sensitivities. Red dots represent MS measurements from 541 
the HFA, blue dots from the CMP. The shaded grey area indicates the 95 % limits of agreement 542 
on the test-retest difference. 95% Limits of agreement were narrower for sensitivities above 543 
or equal to 15 dB, larger between 11 dB and 14 dB and equivalent below 10 dB. The larger 544 
range in the differences was at 14 dB (-27 dB, 27 dB) for CMP and at 12 dB (-24 dB, 25 dB) for 545 
HFA. 546 
